Point Biopharma
在场
Point Biopharma 的所有者是 Eli Lilly.
是其中之一......
- Forbes Global 2000 (#174);
- Fortune 500 (#127);
- Global Fortune 500 (#455);
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Eli Lilly 是一家在股票代码 LLY (US) 下上市的公司。
Eli Lilly 在 18 个国家有直接业务。Eli Lilly 拥有 25家子公司，其中包括 Dice Therapeutics、Eli Lilly APAC 和 Eli Lilly Argentina。
他们在：
涉及Eli Lilly的并购和融资。
- Eli Lilly has announced the acquisition of Point Biopharma (公布2023十二月5号).
- Eli Lilly has announced the acquisition of Point Biopharma (公布2023十月6号).
高管
查看带有其 4 名主要高管的组织结构图
Point Biopharma 搜索最多的简介
- Jessica Jensen, Executive Vice President, Clinical Development
- Bill Demers, Chief Financial Officer
- Robin Hallett, Senior Vice President, Discovery and Translational ...
高管在Eli Lilly变化
- Thomas FuchsThomas Fuchs 将于202410月20作为 Chief Artificial Intelligence Officer 加入公司 (新闻发布的2024十月9号).
- Marschall Runge, Director, 将于 20248月30 退休 (新闻发布的2024八月20号).
- Gordon Brooks 曾任 Group Vice President, Controller and Corporate Strategy, 现升职为 Interim Chief Financial Officer and Group Vice President, Controller and Strategy (新闻发布的2024七月22号).
创建提醒
跟踪 Point Biopharma 的高管变动
生物技术
Eli Lilly 拥有 2,316 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
- TuHura Biosciences and Kintara Therapeutics have merged (公布2024十月20号)..
生物技术 行业的其他推荐联系人
消息
Point Biopharma 的最新新闻稿
- Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer | POINT Biopharma
- POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights | POINT Biopharma
- Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies | POINT Biopharma
- POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands | POINT Biopharma
- POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights | POINT Biopharma
- ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177 | POINT Biopharma
- News & Company Announcements | POINT Biopharma
- POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands | POINT Biopharma
- POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI’s Annual Congress | POINT Biopharma
- POINT Biopharma Announces Appointment of Dr. Bridget Martell to its Board of Directors | POINT Biopharma
- View more press releases Close
通过电子邮件
